Comparison between long- and short-acting erythropoiesis-stimulating agents in the period required for haemoglobin stabilisation in treatment of anaemia in patients with chronic kidney disease

Takahiro Hayashi, Tadashi Nagamatsu, Ayako Matsushita, Tomohiro Mizuno, Seira Nishibe, Ayaka Noguchi, Rina Kato, Takahiro Toda, Junko Tanaka, Hiroshi Takahashi, Hiroki Hayashi, Yukio Yuzawa, Shigeki Yamada

研究成果: Article

1 引用 (Scopus)

抜粋

Comparative studies of the potency of long- and short-acting erythropoiesis-stimulating agents (L-ESAs and S-ESAs) on erythropoietic activity in patients with chronic kidney disease without dialysis have not been performed, although L-ESAs are used in many countries. We performed a retrospective analysis of non-dialysis (ND) patients who had received L-ESA or S-ESA. More days were needed for the S-ESA-treated group (368 d) to reach the haemoglobin (Hb) reference range than for the L-ESA-treated group (126 d). Therefore, we investigated risk factors that influence the period until the Hb level reaches the reference range. Patients were classified into two groups by the period until the Hb level was stabilised within the reference range: the short- and long-term group. Two risk factors for delayed Hb stabilisation were identified: age ≥60 years; and administration of an S-ESA for initial treatment. These findings suggest that the Hb level should be carefully monitored during ESA therapy in elderly ND patients, and that the ESA dose should be increased or L-ESA therapy should be utilised to treat renal anaemia.

元の言語English
ページ(範囲)740-745
ページ数6
ジャーナルBiological and Pharmaceutical Bulletin
38
発行部数5
DOI
出版物ステータスPublished - 01-05-2015

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science

フィンガープリント Comparison between long- and short-acting erythropoiesis-stimulating agents in the period required for haemoglobin stabilisation in treatment of anaemia in patients with chronic kidney disease' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用